SAGE Therapeutics (SAGE) Receives a Hold from RBC Capital

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price target of $15.00. The company’s shares closed yesterday at $13.58.

According to TipRanks, Abrahams is a 4-star analyst with an average return of 6.5% and a 46.98% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Regeneron, SAGE Therapeutics, and Biogen.

In addition to RBC Capital, SAGE Therapeutics also received a Hold from Needham’s Ami Fadia in a report issued yesterday. However, on the same day, Bank of America Securities reiterated a Sell rating on SAGE Therapeutics (NASDAQ: SAGE).

Based on SAGE Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2.72 million and a GAAP net loss of $201.63 million. In comparison, last year the company earned a revenue of $1.74 million and had a GAAP net loss of $137.32 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

SAGE Therapeutics (SAGE) Company Description:

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.